Clinical trials: HDV
Hepatitis D
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
- Trial name
- NCT05467553
- Testing
- Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Hepatitis D, Hepatitis B
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infection live in China while we…
- Conditions
- Hepatitis D, Hepatitis B, Antibodies; Anti-D, RNA Virus Infections
- Trial name
- NCT05394623
- Testing
- HDV-Ab (IgG), HDV-RNA, RNA genotype
- Volunteers
- 5,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatitis Delta Virus
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
The Phase 3 LIMT-2 study will evaluate the safety and efficacy of Peginterferon Lambda treatment for 48 weeks with 24 weeks follow-up compared to no treatment for 12 weeks in patients chronically infected with HDV.
- Trial name
- LIMT-2 (NCT05070364)
- Testing
- Peginterferon Lambda-1a
- Where
- 48 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- Eiger BioPharmaceuticals
Hepatitis D
The Hepatitis Delta International Network
Hepatitis delta is a major health problem, not only because of the severity of the disease, but also due to the lack of effective antiviral treatment.
- Trial name
- HDIN (NCT02375906)
- Where
- 18 sites in Austria, Belgium and 10 more
- Volunteers
- 2,000 people
- Sponsor
- HepNet Study House, German Liverfoundation
Hepatitis D, Chronic
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.
- Trial name
- REEF-D (NCT04535544)
- Testing
- JNJ-73763989, Entecavir (ETV) monohydrate, Tenofovir disoproxil
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 52 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis C
HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients
A Phase II, Open Label, Multi-Center, Proof-Of-Concept Study determing whether treatment with HDV-Interferon (HDV-IFN), by oral or subcutaneous (injection) routes, and ribavirin results in similar efficacy [Rapid Virologic…
- Trial name
- NCT00703872
- Testing
- Oral HDV-Interferon + ribavarin, Injectable HDV-Interferon + ribavarin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Hepasome Pharmaceuticals
HDV, HDV Infection
D-SOLVE Cohorts (Cohort A and B)
Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death.
- Conditions
- HDV, HDV Infection, Chronic Liver Disease
- Trial name
- HDV750 (NCT06160635)
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 750 people
- Sponsor
- Hannover Medical School
Chronic Hepatitis D Infection, Fibrosis, Liver
Find HDV and Determine Its Status in Turkey
The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast.
- Conditions
- Chronic Hepatitis D Infection, Fibrosis, Liver, Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- SITUHDVATION (NCT06248580)
- Testing
- Anti Delta
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Yaşar Bayındır, MD
HDV, HDV Infection
ePro Diary - HDV ( MACROLIVER )
This study is part of the MACROLIVER Project, which aims to develop a digital tool for patients and their caregivers to manage liver diseases.
- Conditions
- HDV, HDV Infection, Hepatitis
- Trial name
- NCT07442760
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Type 1 Diabetes
Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes
Single-center, double-blind, random-sequence study assessing the HDV dose-response relationship to Endogenous Glucose Production (EGP), Free Fatty Acids (FFA) and Glucose Disposal Rate (GDR) during a euglycemic clamp procedure…
- Trial name
- NCT05689424
- Testing
- HDV-Insulin Lispro
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Chronic Hepatitis D
Burden of Hepatitis D Virus (HDV) Infection in Italy
The circulation of the Hepatitis D Virus (HDV) has considerably diminished in Italy, secondary to the control of the Hepatitis B Virus (HBV) with vaccination; this has led to the perception that HDV is vanishing and has reduced…
- Trial name
- HDV Describe (NCT05723068)
- Where
- 36 sites in Italy
- Volunteers
- 515 people
- Sponsor
- University of Turin, Italy
Chronic Hepatitis B Infection
Hepatitis B Infection Surveillance
France is a low-endemicity country for hepatitis B virus (HBV) infection. In 2016, the prevalence of chronic HBV infection in the general population was estimated at 0.3%, corresponding to more than 135,000 HBsAg-positive…
- Trial name
- HEPB-SURVEY (NCT07727187)
- Where
- France
- Volunteers
- 1,360 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis Delta Virus
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral…
- Trial name
- D-LIVR (NCT03719313)
- Testing
- Lonafarnib, Ritonavir, PEG IFN-alfa-2a
- Where
- 116 sites in United States, Belgium and 20 more
- Volunteers
- 407 people
- Sponsor
- Eiger BioPharmaceuticals
Hepatitis D
HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
The aim of this project is to set up a cross-sectional cohort study (France, Germany, The Netherlands, Poland, Spain, Switzerland, Italy, United Kingdom and Portugal) to assess the implementation of EACS guidelines for…
- Trial name
- NCT06264583
- Testing
- HDV screening
- Where
- Germany
- Volunteers
- 8,000 people
- Sponsor
- University Hospital, Bonn
Hepatitis D, Chronic
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
- Trial name
- LIMT (NCT02765802)
- Testing
- Peginterferon Lambda-1A
- Where
- 4 sites in Israel, New Zealand and 1 more
- Volunteers
- 33 people
- Sponsor
- EIT Pharma, Inc.
Chronic Viral Hepatitis B Without Delta-agent
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
The goal of chronic hepatitis B (CHB) treatment is complete and permanent eradication of hepatitis B virus (HBV) from patient's body, which is best represented by serum HBsAg loss accompanied by undetectable serum HBV DNA level.
- Trial name
- TERESA (NCT01595685)
- Testing
- Telbivudine, Entecavir
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Asan Medical Center
Liver Disease, Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Background: Infection with hepatitis D virus leads to a chronic liver disease with no effective treatment. Lonafarnib has improved hepatitis D virus levels in blood, but the medication still needs more research.
- Trial name
- NCT03600714
- Testing
- Peg-interferon lambda, Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis D, Transmission
Mother-to-child Hepatitis D Transmission
HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication.
- Trial name
- NCT02044055
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hopital Lariboisière
Delta Hepatitis
Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Virus (HDV) Using Capillary Blood on Blotting Paper (DBS)
The Delta hepatitis virus (HDV) is a satellite virus that requires the presence of hepatitis B virus (HBV) for infection. Approximately 5% of HBV-infected individuals, or about 12 million people globally, are also carriers of…
- Trial name
- SACADE (NCT06649396)
- Testing
- Dried Blood Spot, Analysis on plasma
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Diabetes Mellitus, Type 1
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study
- Trial name
- NCT03096392
- Testing
- HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Diasome Pharmaceuticals